Sunday 18 October 2026
Export INO’s income statement to Excel — free account
Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65,300.00, down 70.0% from fiscal 2024. In the quarter to June 2026, revenue fell 83.2%, EPS grew 88.5% and free cash flow grew 13.4%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.99
0.05
−4.81%
Follow INO
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
1 | 2 | 4 | 2 | 2 | 3 | 2 | 2 | 4 | 2 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
211.46 | 70.12 | 179.10 | 35.34 | 587.16 | 185.17 | 79.19 | 12.14 | 9.06 | 14.63 |
Altman Z-Score |
(36.80) | (23.34) | (13.77) | (5.96) | 2.00 | 8.33 | (7.78) | (3.24) | 0.02 | 1.86 |
Altman Z″-Score (non-manufacturers) |
(85.44) | (51.27) | (30.07) | (13.11) | (2.61) | 4.36 | (19.06) | (15.55) | (5.16) | (5.49) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(4.21) | (2.53) | (5.67) | (9.98) | (27.50) | (26.79) | (23.70) | (21.41) | (27.43) | (34.72) |
Beneish M-Score |
— | (2.51) | (3.11) | 0.10 | (4.47) | 2.28 | (3.03) | (3.82) | (3.52) | (1.60) |
P/B ratio |
3.39 | 0.73 | 1.27 | 1.63 | 2.61 | 2.98 | 60.25 | 4.25 | 2.68 | 4.19 |
Price to Tangible BV |
6.01 | 0.86 | 1.39 | 1.73 | 2.70 | 3.07 | 0.00 | 5.16 | 3.04 | 4.92 |
EV/Sales |
102.86 | (39.21) | 24.44 | 12.31 | 369.46 | 132.14 | 76.15 | 9.47 | 6.04 | 11.67 |
EV/EBITDA |
0.00 | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(0.45) | 0.27 | (0.16) | (0.58) | (3.04) | (5.50) | (3.20) | (3.93) | (4.04) | (6.60) |
EV/FCF |
(0.45) | 0.27 | (0.17) | (0.58) | (3.03) | (5.48) | (3.19) | (3.86) | (3.51) | (6.30) |
Quick Ratio |
1.34 | 2.70 | 3.47 | 2.73 | 6.23 | 10.33 | 2.86 | 2.42 | 3.78 | 2.77 |
Current Ratio |
1.40 | 2.77 | 3.60 | 3.25 | 6.82 | 11.30 | 2.94 | 2.49 | 3.91 | 2.84 |
Net Debt/EBITDA |
0.70 | 0.85 | 1.14 | 0.90 | 1.31 | 3.29 | 0.12 | 0.91 | 1.60 | 1.44 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 4.77% | 3.02% | 3.46% | 53.51% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.07 | 0.04 | 0.04 | 14.25 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.02 | 0.03 | 0.19 | 0.23 | 0.18 |
Operating CF/Net income |
1.04 | 0.97 | 0.92 | 0.77 | 0.71 | 1.07 | 0.82 | 0.76 | 0.72 | 0.85 |
Capex/Depreciation |
(0.10) | (0.30) | 0.37 | (0.23) | (0.19) | (0.33) | (0.18) | (0.41) | (2.45) | (0.88) |
Interest Coverage |
— | (632.16) | (117.71) | (213.38) | (155.56) | (14.26) | (13.98) | — | (3,229.46) | — |
| (183.47%) | (115.42%) | (79.55%) | (89.97%) | (70.55%) | (71.34%) | (258.25%) | (84.50%) | (66.35%) | (49.27%) | |
| (90.61%) | (75.49%) | (52.02%) | (66.27%) | (58.64%) | (48.68%) | (86.79%) | (60.92%) | (48.87%) | (38.05%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (1,413.97%) | (113.79%) | 0.00% | (1,013.93%) | (347.05%) | (256.00%) |
Return on Tangible Assets |
(425.11%) | (162.10%) | (116.98%) | (123.76%) | (75.88%) | (37.75%) | (159.18%) | (141.63%) | (72.73%) | (82.12%) |
Average Days of Receivables |
0.00 | 2,009.51 | 1,055.17 | 417.49 | 1,651.84 | 938.89 | 180.38 | 48.55 | 56.11 | 171.00 |
Research and Development Expense of Revenue |
83,012.10% | 34,720.06% | 10,417.86% | 1,828.54% | 14,043.29% | 1,271.66% | 2,140.55% | 312.51% | 233.47% | 250.82% |
Selling, General and Administrative Expense of Revenue |
50,046.86% | 16,986.36% | 5,719.00% | 878.80% | 3,028.65% | 502.59% | 661.57% | 96.17% | 67.01% | 67.55% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.04 | 0.03 | 0.03 | 0.10 | 0.12 | 0.09 | 0.10 |
Share Based Compensation of Revenue |
5,751.61% | 3,028.05% | 1,330.83% | 219.79% | 1,483.93% | 211.13% | 265.12% | 34.95% | 30.96% | 29.63% |
Graham Net Nets |
0.13 | 1.07 | 0.67 | 0.52 | 0.34 | 0.29 | (0.14) | 0.12 | 0.24 | 0.14 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(96.55%) | (218.03%) | (91.06%) | (77.66%) | (29.07%) | (12.55%) | (36.68%) | (26.01%) | (22.87%) | (14.15%) |
Free Cash Flow Yield |
(108.01%) | (208.64%) | (78.97%) | (59.84%) | (20.74%) | (13.02%) | (30.11%) | (20.23%) | (19.00%) | (12.66%) |
Revenue per Share |
0.00 | 0.01 | 0.04 | 0.52 | 0.10 | 0.57 | 0.50 | 3.95 | 6.20 | 5.80 |
Operating CF per Share |
(1.89) | (3.83) | (5.61) | (10.87) | (12.40) | (13.77) | (11.90) | (9.54) | (9.28) | (10.26) |
Capex per Share |
(0.01) | (0.02) | 0.27 | (0.05) | (0.07) | (0.12) | (0.12) | (0.27) | (1.36) | (0.48) |
Free Cash Flow per Share |
(1.90) | (3.85) | (5.34) | (10.92) | (12.47) | (13.89) | (12.02) | (9.81) | (10.64) | (10.74) |
Cash per Share |
1.25 | 3.47 | 6.55 | 12.72 | 23.06 | 31.86 | 10.89 | 10.54 | 18.71 | 17.18 |
Shareholders Equity per Share |
0.51 | 2.52 | 5.29 | 11.18 | 22.97 | 35.69 | 0.66 | 11.29 | 20.92 | 20.23 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.51 | 2.52 | 5.29 | 11.18 | 22.97 | 35.69 | 0.66 | 11.29 | 20.92 | 20.23 |
Free Cash Flow |
(88.92) | (104.51) | (118.47) | (217.18) | (216.94) | (179.50) | (98.84) | (75.64) | (72.50) | (65.49) |
Working Capital |
17.45 | 62.50 | 110.54 | 218.37 | 382.70 | 429.46 | 62.21 | 52.52 | 102.96 | 80.77 |
Capital Expenditures |
(0.29) | (0.43) | 5.90 | (0.97) | (1.23) | (1.52) | (0.99) | (2.08) | (9.29) | (2.94) |
Net Current Asset Value |
10.91 | 53.14 | 99.51 | 189.07 | 352.17 | 392.54 | (44.35) | 43.73 | 93.61 | 74.27 |
EV/EBIT |
0.00 | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
4.38 | 1.97 | (7.09) | 0.09 | 0.69 | 0.21 | 0.24 | 0.07 | 0.22 | 0.08 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.18 | 0.39 | 3.23 | 0.54 | 0.36 | 0.41 | 0.43 | 0.32 | 0.21 | 0.37 |
Cash ROIC |
(107.63%) | (64.26%) | (45.11%) | (44.15%) | (26.59%) | (20.14%) | (57.48%) | (44.95%) | (26.86%) | (28.71%) |
Accounts Receivable Turnover |
0.00 | 0.12 | 0.12 | 1.04 | 0.13 | 0.70 | 1.35 | 5.78 | 3.66 | 2.96 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Average Receivables |
— | 1.80 | 7.07 | 9.89 | 13.55 | 10.55 | 3.04 | 5.27 | 11.53 | 11.95 |
Average Payables |
14.34 | 19.23 | 50.91 | 64.55 | 35.02 | 20.41 | 21.54 | 24.16 | 22.44 | 16.95 |
Average Assets |
93.75 | 142.07 | 259.74 | 422.24 | 517.86 | 341.86 | 137.53 | 159.18 | 180.47 | 193.77 |
Average Common Equity |
46.30 | 92.93 | 169.86 | 311.02 | 430.41 | 233.27 | 46.22 | 114.76 | 132.93 | 149.66 |
Columns are period end dates